A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma.
Principal investigator
Anne Des Roches, M.D.
Selection criteria
To be eligible for this research study, your child must:
- Be between 5 and 17 years of age
- Have had a history of ragweed allergies s for at least 1 year (at least 1 season for ages 4 to 6 years) or at least 2 years (at least 2 seasons for ages 7 to 17 years).
There are other requirements that your child must meet to participate in the study, which we
will review during the screening process.
Contribution of the patient and/or his parents
After a screening phase of up to 12 months, you will receive assigned treatment for up to 28
weeks and followed up with a phone call for an additional 14 days. The study doctor or staff will
discuss with you when and on which days to report to the clinic.
Contact information
Isabelle Boisvert
Clinical research assistant
isabelle.boisvert@recherche‐ste‐justine.qc.ca
Research project website